New hope for rare kidney cancer: targeted drug savolitinib faces off against standard therapy

NCT ID NCT03091192

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times

Summary

This phase 3 study compares a new drug, savolitinib, to the standard drug sunitinib in 60 people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib is better at stopping the cancer from growing and to check its side effects. Participants take one of the two pills by mouth daily.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

Atlanta, Georgia, 30322, United States
Research Site

Chicago, Illinois, 60637, United States
Research Site

Iowa City, Iowa, 52242, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

Kansas City, Missouri, 64132, United States
Research Site

New York, New York, 10021, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Barretos, 14784-400, Brazil
Research Site

Curitiba, 81520-060, Brazil
Research Site

Passo Fundo, 99010-080, Brazil
Research Site

Pelotas, 096015-280, Brazil
Research Site

Porto Alegre, 90050-170, Brazil
Research Site

Porto Alegre, 90610-000, Brazil
Research Site

Porto Alegre, 91350-200, Brazil
Research Site

Rio de Janeiro, 22793-080, Brazil
Research Site

São José do Rio Preto, 15090-000, Brazil
Research Site

São Paulo, 01246-000, Brazil
Research Site

São Paulo, 01323-903, Brazil
Research Site

Bordeaux, 33000, France
Research Site

Vandœuvre-lès-Nancy, 54519, France
Research Site

Villejuif, 94805, France
Research Site

Arezzo, 52100, Italy
Research Site

Meldola, 47014, Italy
Research Site

Milan, 20133, Italy
Research Site

Modena, 41100, Italy
Research Site

Orbassano, 10043, Italy
Research Site

Pavia, 27100, Italy
Research Site

Roma, 00152, Italy
Research Site

Krasnoyarsk, 660133, Russia
Research Site

Moscow, 105077, Russia
Research Site

Moscow, 115478, Russia
Research Site

Moscow, 115522, Russia
Research Site

Moscow, RU-121356, Russia
Research Site

Murmansk, 183047, Russia
Research Site

Nizhny Novgorod, 603109, Russia
Research Site

Obninsk, 249036, Russia
Research Site

Omsk, 644013, Russia
Research Site

Saint Petersburg, 194017, Russia
Research Site

Saint Petersburg, 195271, Russia
Research Site

Saint Petersburg, 196603, Russia
Research Site

Volgograd, 400138, Russia
Research Site

Daejeon, 35015, South Korea
Research Site

Goyang-si, 10408, South Korea
Research Site

Hwasun-gun, 58128, South Korea
Research Site

Incheon, 21565, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06273, South Korea
Research Site

Seoul, 120-752, South Korea
Research Site

Seoul, 6351, South Korea
Research Site

Dnipro, 49005, Ukraine
Research Site

Dnipro, 49102, Ukraine
Research Site

Ivano-Frankivsk, 76018, Ukraine
Research Site

Kharkiv Region, 61070, Ukraine
Research Site

Kyiv, 03022, Ukraine
Research Site

Kyiv, 03115, Ukraine
Research Site

Odesa, 65055, Ukraine
Research Site

Sumy, 40022, Ukraine

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

savolitinib

What this could lead to

If it works, this could provide a more effective treatment option for people with a specific type of kidney cancer that has spread.

What could go wrong

This is a phase 3 trial, but it's small (60 people) and results may not apply to all patients. Savolitinib may not prove better than sunitinib and could have unexpected side effects.

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm carcinoma kidney cancer kidney disorder Neoplasms by Site renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA CARCINOMA, RENAL CELL ENZYME INHIBITORS KIDNEY DISEASES KIDNEY NEOPLASMS NEOPLASMS BY SITE NEOPLASMS BY SITE PROTEIN KINASE INHIBITORS UROLOGIC NEOPLASMS UROLOGIC NEOPLASMS